Osteoporosis Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Type (Calcitonin, Bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), Rank Ligand (RANKL) Inhibitor, Parathyroid Hormone-Related Protein (PTHrP) Analog, Others); Route of Administration (Oral, Injectable, Others); Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) and Geography

Report Code: TIPRE00004071 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Osteoporosis is a medical condition that affects people and is characterised by decreased bone density and quality. Furthermore, with this medical condition, the bones become porous, making them more fragile and prone to fractures. The disorder is caused by an excessive amount of the hormone parathyroid. The condition can result in serious fractures, which can be harmful to the patient's health. As a result, the condition requires therapy, which involves the administration of osteoporosis drugs. Some of the drugs for osteoporosis available in the market include, parathyroid hormone therapy, calcitonin, bisphosphonates selective estrogen inhibitors modulator (SERM), and RANK ligand inhibitors. These drugs are administered through various routes in the body such as oral route and intravenous route.

MARKET SCOPE

The "Global Osteoporosis Treatment Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the osteoporosis treatment market with detailed market segmentation by drug type, route of administration and distribution channel. The report provides key statistics on the market status of the leading osteoporosis treatment market players and offers key trends and opportunities in the market.MARKET SEGMENTATION

  •   Based on drug type the market is segmented as, calcitonin, bisphosphonates, selective estrogen receptor modulators (SERMs), rank ligand (RANKL) inhibitor, parathyroid hormone-related protein (PTHrP) analog and others.
  •   Based on route of administration the market is segmented as, oral, injectable and others.
  •   Based on distribution channel the market is segmented as, hospitals, retail pharmacies and online pharmacies.

MARKET DYNAMICS
Drivers:

  •   Increasing prevalence of osteoporosis across the globe.
  •   Increasing geriatric population across the globe and adoption of sedentary lifestyles.
  •   Risk factors such as, older age, unhealthy lifestyles, tobacco consumption, alcoholism presence of comorbidities.
  •   Increasing awareness about osteoporosis treatment and effective management of disease.
  •   Presence of robust pipeline of therapeutic agents for treatment of osteoporosis.

Restraints:

  •   However, side effects from prolonged treatment and time consuming product approval procedure are expected to restrain market growth.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The osteoporosis treatment market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the osteoporosis treatment market in these regions.

IMPACT OF COVID-19 ON OSTEOPOROSIS TREATMENT MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS

The report covers key developments in the osteoporosis treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from osteoporosis treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for osteoporosis treatment in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the osteoporosis treatment market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
  •   Teva Pharmaceutical Industries Ltd.
  •   Mylan N.V.
  •   Dr. Reddy's Laboratories Ltd
  •   Takeda Pharmaceutical Company Limited
  •   F. Hoffmann-La Roche Ltd
  •   Radius Health, Inc.
  •   GlaxoSmithKline plc.
  •   Novartis AG
  •   Amgen Inc
  •   Asahi Kasei Pharma Corporation
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
  • TABLE OF CONTENTS

    1. INTRODUCTION
    1.1. SCOPE OF THE STUDY
    1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
    1.3. MARKET SEGMENTATION
    1.3.1 Osteoporosis Treatment Market - By Drug Type
    1.3.2 Osteoporosis Treatment Market - By Route of Administration
    1.3.3 Osteoporosis Treatment Market - By Distribution Channel
    1.3.4 Osteoporosis Treatment Market - By Region
    1.3.4.1 By Country

    2. KEY TAKEAWAYS

    3. RESEARCH METHODOLOGY

    4. OSTEOPOROSIS TREATMENT MARKET LANDSCAPE
    4.1. OVERVIEW
    4.2. PORTER'S FIVE FORCES ANALYSIS
    4.2.1 Bargaining Power of Buyers
    4.2.1 Bargaining Power of Suppliers
    4.2.1 Threat of Substitute
    4.2.1 Threat of New Entrants
    4.2.1 Competitive Rivalry
    4.3. EXPERT OPINIONS

    5. OSTEOPOROSIS TREATMENT MARKET - KEY MARKET DYNAMICS
    5.1. KEY MARKET DRIVERS
    5.2. KEY MARKET RESTRAINTS
    5.3. KEY MARKET OPPORTUNITIES
    5.4. FUTURE TRENDS
    5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

    6. OSTEOPOROSIS TREATMENT MARKET - GLOBAL MARKET ANALYSIS
    6.1. OSTEOPOROSIS TREATMENT - GLOBAL MARKET OVERVIEW
    6.2. OSTEOPOROSIS TREATMENT - GLOBAL MARKET AND FORECAST TO 2028
    6.3. MARKET POSITIONING/MARKET SHARE

    7. OSTEOPOROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DRUG TYPE
    7.1. OVERVIEW
    7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
    7.3. CALCITONIN
    7.3.1. Overview
    7.3.2. Calcitonin Market Forecast and Analysis
    7.4. BISPHOSPHONATES
    7.4.1. Overview
    7.4.2. Bisphosphonates Market Forecast and Analysis
    7.5. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS)
    7.5.1. Overview
    7.5.2. Selective Estrogen Receptor Modulators (SERMs) Market Forecast and Analysis
    7.6. RANK LIGAND (RANKL) INHIBITOR
    7.6.1. Overview
    7.6.2. Rank Ligand (RANKL) Inhibitor Market Forecast and Analysis
    7.7. PARATHYROID HORMONE-RELATED PROTEIN (PTHRP) ANALOG
    7.7.1. Overview
    7.7.2. Parathyroid Hormone-Related Protein (PTHrP) Analog Market Forecast and Analysis
    7.8. OTHERS
    7.8.1. Overview
    7.8.2. Others Market Forecast and Analysis
    8. OSTEOPOROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - ROUTE OF ADMINISTRATION
    8.1. OVERVIEW
    8.2. ROUTE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
    8.3. ORAL
    8.3.1. Overview
    8.3.2. Oral Market Forecast and Analysis
    8.4. INJECTABLE
    8.4.1. Overview
    8.4.2. Injectable Market Forecast and Analysis
    8.5. OTHERS
    8.5.1. Overview
    8.5.2. Others Market Forecast and Analysis
    9. OSTEOPOROSIS TREATMENT MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
    9.1. OVERVIEW
    9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
    9.3. HOSPITALS
    9.3.1. Overview
    9.3.2. Hospitals Market Forecast and Analysis
    9.4. RETAIL PHARMACIES
    9.4.1. Overview
    9.4.2. Retail Pharmacies Market Forecast and Analysis
    9.5. ONLINE PHARMACIES
    9.5.1. Overview
    9.5.2. Online Pharmacies Market Forecast and Analysis

    10. OSTEOPOROSIS TREATMENT MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
    10.1. NORTH AMERICA
    10.1.1 North America Osteoporosis Treatment Market Overview
    10.1.2 North America Osteoporosis Treatment Market Forecasts and Analysis
    10.1.3 North America Osteoporosis Treatment Market Forecasts and Analysis - By Drug Type
    10.1.4 North America Osteoporosis Treatment Market Forecasts and Analysis - By Route of Administration
    10.1.5 North America Osteoporosis Treatment Market Forecasts and Analysis - By Distribution Channel
    10.1.6 North America Osteoporosis Treatment Market Forecasts and Analysis - By Countries
    10.1.6.1 United States Osteoporosis Treatment Market
    10.1.6.1.1 United States Osteoporosis Treatment Market by Drug Type
    10.1.6.1.2 United States Osteoporosis Treatment Market by Route of Administration
    10.1.6.1.3 United States Osteoporosis Treatment Market by Distribution Channel
    10.1.6.2 Canada Osteoporosis Treatment Market
    10.1.6.2.1 Canada Osteoporosis Treatment Market by Drug Type
    10.1.6.2.2 Canada Osteoporosis Treatment Market by Route of Administration
    10.1.6.2.3 Canada Osteoporosis Treatment Market by Distribution Channel
    10.1.6.3 Mexico Osteoporosis Treatment Market
    10.1.6.3.1 Mexico Osteoporosis Treatment Market by Drug Type
    10.1.6.3.2 Mexico Osteoporosis Treatment Market by Route of Administration
    10.1.6.3.3 Mexico Osteoporosis Treatment Market by Distribution Channel
    10.2. EUROPE
    10.2.1 Europe Osteoporosis Treatment Market Overview
    10.2.2 Europe Osteoporosis Treatment Market Forecasts and Analysis
    10.2.3 Europe Osteoporosis Treatment Market Forecasts and Analysis - By Drug Type
    10.2.4 Europe Osteoporosis Treatment Market Forecasts and Analysis - By Route of Administration
    10.2.5 Europe Osteoporosis Treatment Market Forecasts and Analysis - By Distribution Channel
    10.2.6 Europe Osteoporosis Treatment Market Forecasts and Analysis - By Countries
    10.2.6.1 Germany Osteoporosis Treatment Market
    10.2.6.1.1 Germany Osteoporosis Treatment Market by Drug Type
    10.2.6.1.2 Germany Osteoporosis Treatment Market by Route of Administration
    10.2.6.1.3 Germany Osteoporosis Treatment Market by Distribution Channel
    10.2.6.2 France Osteoporosis Treatment Market
    10.2.6.2.1 France Osteoporosis Treatment Market by Drug Type
    10.2.6.2.2 France Osteoporosis Treatment Market by Route of Administration
    10.2.6.2.3 France Osteoporosis Treatment Market by Distribution Channel
    10.2.6.3 Italy Osteoporosis Treatment Market
    10.2.6.3.1 Italy Osteoporosis Treatment Market by Drug Type
    10.2.6.3.2 Italy Osteoporosis Treatment Market by Route of Administration
    10.2.6.3.3 Italy Osteoporosis Treatment Market by Distribution Channel
    10.2.6.4 Spain Osteoporosis Treatment Market
    10.2.6.4.1 Spain Osteoporosis Treatment Market by Drug Type
    10.2.6.4.2 Spain Osteoporosis Treatment Market by Route of Administration
    10.2.6.4.3 Spain Osteoporosis Treatment Market by Distribution Channel
    10.2.6.5 United Kingdom Osteoporosis Treatment Market
    10.2.6.5.1 United Kingdom Osteoporosis Treatment Market by Drug Type
    10.2.6.5.2 United Kingdom Osteoporosis Treatment Market by Route of Administration
    10.2.6.5.3 United Kingdom Osteoporosis Treatment Market by Distribution Channel
    10.2.6.6 Rest of Europe Osteoporosis Treatment Market
    10.2.6.6.1 Rest of Europe Osteoporosis Treatment Market by Drug Type
    10.2.6.6.2 Rest of Europe Osteoporosis Treatment Market by Route of Administration
    10.2.6.6.3 Rest of Europe Osteoporosis Treatment Market by Distribution Channel
    10.3. ASIA-PACIFIC
    10.3.1 Asia-Pacific Osteoporosis Treatment Market Overview
    10.3.2 Asia-Pacific Osteoporosis Treatment Market Forecasts and Analysis
    10.3.3 Asia-Pacific Osteoporosis Treatment Market Forecasts and Analysis - By Drug Type
    10.3.4 Asia-Pacific Osteoporosis Treatment Market Forecasts and Analysis - By Route of Administration
    10.3.5 Asia-Pacific Osteoporosis Treatment Market Forecasts and Analysis - By Distribution Channel
    10.3.6 Asia-Pacific Osteoporosis Treatment Market Forecasts and Analysis - By Countries
    10.3.6.1 Australia Osteoporosis Treatment Market
    10.3.6.1.1 Australia Osteoporosis Treatment Market by Drug Type
    10.3.6.1.2 Australia Osteoporosis Treatment Market by Route of Administration
    10.3.6.1.3 Australia Osteoporosis Treatment Market by Distribution Channel
    10.3.6.2 China Osteoporosis Treatment Market
    10.3.6.2.1 China Osteoporosis Treatment Market by Drug Type
    10.3.6.2.2 China Osteoporosis Treatment Market by Route of Administration
    10.3.6.2.3 China Osteoporosis Treatment Market by Distribution Channel
    10.3.6.3 India Osteoporosis Treatment Market
    10.3.6.3.1 India Osteoporosis Treatment Market by Drug Type
    10.3.6.3.2 India Osteoporosis Treatment Market by Route of Administration
    10.3.6.3.3 India Osteoporosis Treatment Market by Distribution Channel
    10.3.6.4 Japan Osteoporosis Treatment Market
    10.3.6.4.1 Japan Osteoporosis Treatment Market by Drug Type
    10.3.6.4.2 Japan Osteoporosis Treatment Market by Route of Administration
    10.3.6.4.3 Japan Osteoporosis Treatment Market by Distribution Channel
    10.3.6.5 South Korea Osteoporosis Treatment Market
    10.3.6.5.1 South Korea Osteoporosis Treatment Market by Drug Type
    10.3.6.5.2 South Korea Osteoporosis Treatment Market by Route of Administration
    10.3.6.5.3 South Korea Osteoporosis Treatment Market by Distribution Channel
    10.3.6.6 Rest of Asia-Pacific Osteoporosis Treatment Market
    10.3.6.6.1 Rest of Asia-Pacific Osteoporosis Treatment Market by Drug Type
    10.3.6.6.2 Rest of Asia-Pacific Osteoporosis Treatment Market by Route of Administration
    10.3.6.6.3 Rest of Asia-Pacific Osteoporosis Treatment Market by Distribution Channel
    10.4. MIDDLE EAST AND AFRICA
    10.4.1 Middle East and Africa Osteoporosis Treatment Market Overview
    10.4.2 Middle East and Africa Osteoporosis Treatment Market Forecasts and Analysis
    10.4.3 Middle East and Africa Osteoporosis Treatment Market Forecasts and Analysis - By Drug Type
    10.4.4 Middle East and Africa Osteoporosis Treatment Market Forecasts and Analysis - By Route of Administration
    10.4.5 Middle East and Africa Osteoporosis Treatment Market Forecasts and Analysis - By Distribution Channel
    10.4.6 Middle East and Africa Osteoporosis Treatment Market Forecasts and Analysis - By Countries
    10.4.6.1 South Africa Osteoporosis Treatment Market
    10.4.6.1.1 South Africa Osteoporosis Treatment Market by Drug Type
    10.4.6.1.2 South Africa Osteoporosis Treatment Market by Route of Administration
    10.4.6.1.3 South Africa Osteoporosis Treatment Market by Distribution Channel
    10.4.6.2 Saudi Arabia Osteoporosis Treatment Market
    10.4.6.2.1 Saudi Arabia Osteoporosis Treatment Market by Drug Type
    10.4.6.2.2 Saudi Arabia Osteoporosis Treatment Market by Route of Administration
    10.4.6.2.3 Saudi Arabia Osteoporosis Treatment Market by Distribution Channel
    10.4.6.3 U.A.E Osteoporosis Treatment Market
    10.4.6.3.1 U.A.E Osteoporosis Treatment Market by Drug Type
    10.4.6.3.2 U.A.E Osteoporosis Treatment Market by Route of Administration
    10.4.6.3.3 U.A.E Osteoporosis Treatment Market by Distribution Channel
    10.4.6.4 Rest of Middle East and Africa Osteoporosis Treatment Market
    10.4.6.4.1 Rest of Middle East and Africa Osteoporosis Treatment Market by Drug Type
    10.4.6.4.2 Rest of Middle East and Africa Osteoporosis Treatment Market by Route of Administration
    10.4.6.4.3 Rest of Middle East and Africa Osteoporosis Treatment Market by Distribution Channel
    10.5. SOUTH AND CENTRAL AMERICA
    10.5.1 South and Central America Osteoporosis Treatment Market Overview
    10.5.2 South and Central America Osteoporosis Treatment Market Forecasts and Analysis
    10.5.3 South and Central America Osteoporosis Treatment Market Forecasts and Analysis - By Drug Type
    10.5.4 South and Central America Osteoporosis Treatment Market Forecasts and Analysis - By Route of Administration
    10.5.5 South and Central America Osteoporosis Treatment Market Forecasts and Analysis - By Distribution Channel
    10.5.6 South and Central America Osteoporosis Treatment Market Forecasts and Analysis - By Countries
    10.5.6.1 Brazil Osteoporosis Treatment Market
    10.5.6.1.1 Brazil Osteoporosis Treatment Market by Drug Type
    10.5.6.1.2 Brazil Osteoporosis Treatment Market by Route of Administration
    10.5.6.1.3 Brazil Osteoporosis Treatment Market by Distribution Channel
    10.5.6.2 Argentina Osteoporosis Treatment Market
    10.5.6.2.1 Argentina Osteoporosis Treatment Market by Drug Type
    10.5.6.2.2 Argentina Osteoporosis Treatment Market by Route of Administration
    10.5.6.2.3 Argentina Osteoporosis Treatment Market by Distribution Channel
    10.5.6.3 Rest of South and Central America Osteoporosis Treatment Market
    10.5.6.3.1 Rest of South and Central America Osteoporosis Treatment Market by Drug Type
    10.5.6.3.2 Rest of South and Central America Osteoporosis Treatment Market by Route of Administration
    10.5.6.3.3 Rest of South and Central America Osteoporosis Treatment Market by Distribution Channel

    11. INDUSTRY LANDSCAPE
    11.1. MERGERS AND ACQUISITIONS
    11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
    11.3. NEW PRODUCT LAUNCHES
    11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

    12. OSTEOPOROSIS TREATMENT MARKET, KEY COMPANY PROFILES
    12.1. TEVA PHARMACEUTICAL INDUSTRIES LTD.
    12.1.1. Key Facts
    12.1.2. Business Description
    12.1.3. Products and Services
    12.1.4. Financial Overview
    12.1.5. SWOT Analysis
    12.1.6. Key Developments
    12.2. MYLAN N.V.
    12.2.1. Key Facts
    12.2.2. Business Description
    12.2.3. Products and Services
    12.2.4. Financial Overview
    12.2.5. SWOT Analysis
    12.2.6. Key Developments
    12.3. DR. REDDY'S LABORATORIES LTD
    12.3.1. Key Facts
    12.3.2. Business Description
    12.3.3. Products and Services
    12.3.4. Financial Overview
    12.3.5. SWOT Analysis
    12.3.6. Key Developments
    12.4. TAKEDA PHARMACEUTICAL COMPANY LIMITED
    12.4.1. Key Facts
    12.4.2. Business Description
    12.4.3. Products and Services
    12.4.4. Financial Overview
    12.4.5. SWOT Analysis
    12.4.6. Key Developments
    12.5. F. HOFFMANN-LA ROCHE LTD
    12.5.1. Key Facts
    12.5.2. Business Description
    12.5.3. Products and Services
    12.5.4. Financial Overview
    12.5.5. SWOT Analysis
    12.5.6. Key Developments
    12.6. RADIUS HEALTH, INC.
    12.6.1. Key Facts
    12.6.2. Business Description
    12.6.3. Products and Services
    12.6.4. Financial Overview
    12.6.5. SWOT Analysis
    12.6.6. Key Developments
    12.7. GLAXOSMITHKLINE PLC.
    12.7.1. Key Facts
    12.7.2. Business Description
    12.7.3. Products and Services
    12.7.4. Financial Overview
    12.7.5. SWOT Analysis
    12.7.6. Key Developments
    12.8. NOVARTIS AG
    12.8.1. Key Facts
    12.8.2. Business Description
    12.8.3. Products and Services
    12.8.4. Financial Overview
    12.8.5. SWOT Analysis
    12.8.6. Key Developments
    12.9. AMGEN INC.
    12.9.1. Key Facts
    12.9.2. Business Description
    12.9.3. Products and Services
    12.9.4. Financial Overview
    12.9.5. SWOT Analysis
    12.9.6. Key Developments
    12.10. ASAHI KASEI PHARMA CORPORATION
    12.10.1. Key Facts
    12.10.2. Business Description
    12.10.3. Products and Services
    12.10.4. Financial Overview
    12.10.5. SWOT Analysis
    12.10.6. Key Developments

    13. APPENDIX
    13.1. ABOUT THE INSIGHT PARTNERS
    13.2. GLOSSARY OF TERMS
    The List of Companies

    - Teva Pharmaceutical Industries Ltd.
    - Mylan N.V.
    - Dr. Reddy's Laboratories Ltd
    - Takeda Pharmaceutical Company Limited
    - F. Hoffmann-La Roche Ltd
    - Radius Health, Inc.
    - GlaxoSmithKline plc.
    - Novartis AG
    - Amgen Inc
    - Asahi Kasei Pharma Corporation
    - F. Hoffmann-La Roche Ltd
    - Merck Sharp and Dohme Corp
    - Cipla Inc
    TIPRE00004071
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Pricing

    Free

    20%

    customization on Pre-Booking